Clinical Evidence Summary Study Type: Retrospective analysis (not a randomized controlled trial) Participants: 1,131 program completers with BMI 30 Duration: 52-68 weeks Primary Outcome: 19.5% average body weight reduction at 52 weeks Medication: 95.4% compounded semaglutide, 4.6% branded semaglutide Control Group: None Funding/Authors: Ivm Health-affiliated authors (conflict of interest disclosed) Publication: Obesity Pillars , 2025 (PubMed indexed, peer-reviewed) Key Limitation: Self-selected completers
Rising disposable income, investments in healthcare, and higher adoption rates in the Gulf countries
Timing, Temperature, and Pre-Injection Preparation Variables When and how you prepare your skin and body before injecting significantly influences bruising likelihood
At Majestic Aesthetics , were here to guide you every step of the way
The honest answer is that everyones journey is different
Dietitians also find in some cases that the loss of appetite can lead to entirely new eating disorders